<DOC>
	<DOCNO>NCT01764880</DOCNO>
	<brief_summary>Heparanase cleave heparan sulfate ( HS ) chain , natural substrate heparanase , participate degradation remodelling extra-cellular matrix ( ECM ) facilitating , among activity , cell invasion associate cancer metastasis , angiogenesis , inflammation . The heparanase enzyme promise target development new anticancer drug . HS structurally relate heparin present animal specie . As analogue natural substrate heparanase HS , heparin consider potent inhibitor heparanase . SST0001 polymer heparin-like structure . It reduce oxidized N-acetyl heparin , modification cause reduction anticoagulant activity strictly relate anti-heparanase activity . In preclinical murine model SST0001 show significant anti myeloma effect multiple myeloma mouse xenograft model , significant reduction subcutaneous growth different multiple myeloma cell line , SST0001 administer either alone combination dexamethasone . The purpose study determine safety tolerability escalate dos SST0001 treatment advance refractory multiple myeloma .</brief_summary>
	<brief_title>SST0001 ( Roneparstat ) Advanced Multiple Myeloma</brief_title>
	<detailed_description>Multicenter , open label , uncontrolled Phase I First In Man trial advance refractory multiple myeloma , determine Maximum Tolerated Dose ( MTD ) SST0001 give subcutaneously ( sc ) daily 5 10 day , cycle 28 day . A start dose 25 mg ( flat dose ) give daily 5 day ( Day 1 Day 5 ) . In subsequent cohort 25 mg administer daily 10 day ( Day 1 5 Day 8 12 ) . Dose escalation SST0001 administer 10 day perform subsequent cohort , depend toxicity observe . Indirect pharmacokinetics base Activated Partial Thromboplastin Time ( aPTT ) modification patient ( minimum 3 patient cohort ) first cycle treatment direct SST0001 concentration measurement . Pharmacodynamics patient first cycle treatment , base modification coagulation parameter . During study hint anti-tumor activity also evaluate base use surrogate parameter ( monoclonal serum urine protein modification ) .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Advanced , heavily pretreated refractory multiple myeloma ( MM ) . Patient exhaust available anti MM therapy . Age ≥18 year . ECOG ( Eastern Cooperative Oncology Group ) performance status ≤ 2 . Life expectancy 3 month . No concomitant use anticoagulant antiplatelets drug aspirin , NSAIDs ( Nonsteroidal Antiinflammatory Drug ) , Clopidogrel , Unfractionated Heparin , Low Molecular Weight Heparin ( e.g . Enoxaparin ) , Fondaparinux , Dabigatran , Rivaroxaban , Apixaban Warfarin . No platelets diseases allergy anticoagulant . WBC ( White Blood Cell ) ≥2000/µL ; Platelets ≥50,000/µL ; Hb ≥ 8 g/dL . Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) ; AST ( aspartate aminotransferase ) ALT ( alanine aminotransferase ) ≤ 3 x ULN ; serum creatinine ≤ 1.5 x ULN ( Upper Limit Normal ) . aPTT , TT , INR , fibrinogen , Ddimer within ULN . Disease free prior malignancy ≥ 3 year . No acute gastrointestinal bleeding major bleeding ( e.g CNS ) past 2 year significant bleeding history . No known central nervous system involvement myeloma . Capacity understanding nature trial give write informed consent . Unless female patient postmenopausal surgically sterilize , must willing use acceptable method birth control ( hormonal contraceptive , intrauterine device , barrier contraceptive spermicide , abstinence ) duration study . Male patient must agree use acceptable method contraception ( barrier contraceptive abstinence ) duration study . Pregnancy lactation unwillingness use adequate method birth control Ascertained presumptive hypersensitivity active principle and/or formulation ingredient . Active uncontrolled viral , bacterial , fungal infection history HIV , hepatitis B C , infection require systemic antiviral antimicrobial . Grade ≥ 2 toxicity due previous antineoplastic therapy ( except alopecia ) , Grade ≥ 3 peripheral motor sensory neuropathy , 2 week treatment ( CTCAE V4.0 ) . Less 2 week since recent chemotherapy , concurrent chemotherapy . Presence cirrhosis chronic hepatitis . Diagnosis amyloidosis diagnosis plasma cell leukaemia . Presence serious cardiac ( congestive heart failure , angina pectoris , myocardial infarction within one year prior study entry , uncontrolled hypertension arrhythmia ) , neurological psychiatric disorder . Presence uncontrolled intercurrent illness condition judgement investigator would place subject undue risk interfere result study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Heparanase inhibitor</keyword>
	<keyword>Multiple myeloma</keyword>
</DOC>